Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00303992
• Other study ID #: 037517
• Secondary ID: UCSF-037517UCSF-
• Status: Completed
• Phase: Phase 2
• First received: March 15, 2006
• Last updated: January 12, 2018
• Start date: May 2004
• Est. completion date: January 2013

Study information

• Verified date: January 2018
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with irinotecan may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving trastuzumab together with irinotecan works in treating patients with HER2/neu positive metastatic breast cancer.

Description:

OBJECTIVES:

Primary

• Determine the overall objective response-rate (partial and complete) and stable disease rate in patients with HER2/neu positive metastatic breast cancer treated with the combination of irinotecan hydrochloride and trastuzumab (Herceptin®) after prior first- or second-line therapy with trastuzumab combined with other chemotherapeutic agents.

Secondary

• Determine the toxicities of this combination regimen.

• Determine the duration of response and time to disease progression in patients treated with this combination.

• Document development of brain metastases or progression of known metastases in patients treated with this regimen.

OUTLINE: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, 15, and 22 and irinotecan hydrochloride IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Other known NCT identifiers

• NCT00145821

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: January 2013
• Est. primary completion date: November 16, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed metastatic breast carcinoma

• Received 1-3 prior chemotherapy regimens for metastatic disease

• Documented progressive disease

• Repeated courses of the same chemotherapy agent alone or in combination are considered a single regimen

• Prior trastuzumab (Herceptin®) alone or with chemotherapy allowed

• Other biologic agents are not considered a chemotherapy regimen

• Measurable disease

• Patients with bone-only disease who are evaluable by tumor markers (e.g., CA15-3, CEA, or CA27.29) are eligible

• Patients must have prior evidence of correlation of disease activity with changes in tumor marker level

• Confirmation of HER2/neu status by a positive test for gene amplification by fluorescence in situ hybridization or 3+ by immunohistochemistry

• Brain metastases allowed if the following criteria are met:

• Brain metastases were previously treated and are currently stable as documented by head CT scan with contrast or MRI within 4 weeks of study entry

• Patients with existing brain metastases should have stability documented by prior imaging = 8 weeks before the baseline scan

• Hormone-receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• ECOG performance status = 2

• Absolute neutrophil count = 1,000/mm^3

• Platelet count = 100,000/mm^3

• Life expectancy = 12 weeks

• No history of congestive heart failure

• Documented ejection fraction = 45% by MUGA scan or echocardiogram within 1 month of study entry

• Total bilirubin < 3 times upper limit of normal (ULN)

• AST < 3 times ULN (5 times ULN if due to liver involvement)

• Creatinine < 1.5 times ULN

• No history of serious adverse events related to trastuzumab

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No severe, concurrent illness that would prevent compliance with study protocol

• No chronic severe diarrheal illness

• No history of Gilbert's disease or known deficiency in glucuronidation

• No recent or current history of alcoholism or acute viral hepatitis

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No chemotherapy or hormonal therapy within the past 2 weeks

• Prior or concurrent bisphosphonates allowed

• No prior irinotecan (other camptothecins allowed)

• No concurrent radiotherapy

• No ongoing treatment with any other investigational agent

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Biological:
• trastuzumab

Drug:
• irinotecan hydrochloride

Locations

Country	Name	City	State
United States	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall objective response rate (partial and complete responses)		up to 20 months post treatment
Primary	Stable disease rate		up to 20 months post treatment
Secondary	Toxicity		up to 20 months post treatment
Secondary	Duration of response		up to 20 months post treatment
Secondary	Time to disease progression		up to 20 months post treatment
Secondary	Development of brain metastases or progression of known metastases on this treatment		up to 20 months post treatment